The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTPhysicochemical Properties of Antibacterial Compounds: Implications for Drug DiscoveryRosemarie O'Shea and Heinz E. Moser*View Author Information Achaogen Pharmaceuticals Inc., 7000 Shoreline Court, South San Francisco, California 94080* To whom correspondence should be addressed. Phone: +1-650-266-1140 . Fax: +1-650-266-1154. E-mail: [email protected]Cite this: J. Med. Chem. 2008, 51, 10, 2871–2878Publication Date (Web):February 9, 2008Publication History Received2 August 2007Published online9 February 2008Published inissue 1 May 2008https://pubs.acs.org/doi/10.1021/jm700967ehttps://doi.org/10.1021/jm700967ereview-articleACS PublicationsCopyright © 2008 American Chemical SocietyRequest reuse permissionsArticle Views14251Altmetric-Citations523LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-AlertscloseSupporting Info (1)»Supporting Information Supporting Information SUBJECTS:Antimicrobial agents,Bioavailability,Membranes,Pharmaceuticals,Polarity Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
Nikaido, H. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.4.593-656.2003 · Cited by 4,316
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
Cited by
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Self-citationNatural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Predictive compound accumulation rules yield a broad-spectrum antibiotic
Richter, M. F., Drown, B. S., Riley, A. P., Garcia, A., Shirai, T., Svec, R. L., & Hergenrother, P. J. (2017) · Nature · doi:10.1038/nature22308 · Cited by 891
A new antibiotic selectively kills Gram-negative pathogens
Imai, Y., Meyer, K. J., Iinishi, A., Favre-Godal, Q., Green, R., Manuse, S., Caboni, M., Mori, M., Niles, S., Ghiglieri, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1791-1 · Cited by 743
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It
Zgurskaya, H. I., López, C. A., & Gnanakaran, S. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00097 · Cited by 580
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Discovery of a structural class of antibiotics with explainable deep learning
Wong, F., Zheng, E. J., Valeri, J. A., Donghia, N. M., Anahtar, M. N., Omori, S., Li, A., Cubillos-Ruiz, A., Krishnan, A., Jin, W., et al. (2024) · Nature · doi:10.1038/s41586-023-06887-8 · Cited by 458
Strategies to Minimize Antibiotic Resistance
Lee, C.-R., Cho, I., Jeong, B., & Lee, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10094274 · Cited by 446
Molecular mechanisms of antibiotic resistance
Wright, G. D. (2011) · Chemical Communications · doi:10.1039/c0cc05111j · Cited by 443
Choi, U., & Lee, C.-R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00953 · Cited by 382
Optimized arylomycins are a new class of Gram-negative antibiotics
Smith, P. A., Koehler, M. F. T., Girgis, H. S., Yan, D., Chen, Y., Chen, Y., Crawford, J. J., Durk, M. R., Higuchi, R. I., Kang, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0483-6 · Cited by 355
Huigens III, R. W., Morrison, K. C., Hicklin, R. W., Flood Jr, T. A., Richter, M. F., & Hergenrother, P. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1549 · Cited by 320
Liu, B., Trout, R. E. L., Chu, G.-H., McGarry, D., Jackson, R. W., Hamrick, J. C., Daigle, D. M., Cusick, S. M., Pozzi, C., De Luca, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01518 · Cited by 312
Natural Products as a Source for Novel Antibiotics
Moloney, M. G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.001 · Cited by 308
Rare actinomycetes: a potential storehouse for novel antibiotics
Tiwari, K., & Gupta, R. K. (2012) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2011.562482 · Cited by 297
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens
Saxena, D., Maitra, R., Bormon, R., Czekanska, M., Meiers, J., Titz, A., Verma, S., & Chopra, S. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00016-1 · Cited by 217
Bodus, B., O'Malley, K., Dieter, G., Gunawardana, C., & McDonald, W. (2024) · Science of The Total Environment · doi:10.1016/j.scitotenv.2023.167195 · Cited by 76
A data-driven approach for predicting the impact of drugs on the human microbiome
Algavi, Y. M., & Borenstein, E. (2023) · Nature Communications · doi:10.1038/s41467-023-39264-0 · Cited by 54
Metadata
- Authors
- O’Shea, R., & Moser, H. E.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 10
- Pages
- 2871-2878
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2039932426
- Cited by
- 689
- References
- 4
- FWCI
- 40.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.